| answer text |
<p>An initial impact assessment Rescheduling of cannabis-based products for medicinal
use under the Misuse of Drugs Regulations 2001 was published alongside The Misuse
of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations
2018. A copy of this impact assessment is available at the following link:</p><p>
</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>
</p><p>This set out the approach that the Government proposed to take in assessing
the costs and benefits of the change in the law at a population level, with regard
to the rescheduling of CBPM. The analysis is limited to the five medical conditions
where there is most evidence. These five conditions are multiple sclerosis – pain
or muscle spasticity; chemotherapy-induced nausea and vomiting; severe treatment-resistant
epilepsy in children - specifically Dravet Syndrome and Lennox-Gastaut Syndrome only;
chronic pain in adults and appetite and weight loss associated with HIV/AIDS.</p><p>To
further the evidence-base, the National Institute for Health Research has issued two
calls for research in this area and is working with the industry and researchers to
ensure that the evidence is developed in a way that will inform decisions on public
funding. This research will be open to all good quality proposals covering any indication,
including pain and other disorders unresponsive to existing treatments.</p><p> </p>
|
|
